Julie N. Graff, MD, on Pembrolizumab Plus Enzalutamide for Enzalutamide-Resistant Metastatic Castration-Resistant Disease

Posted: Monday, March 16, 2020

Julie Graff, MD, of Oregon Health & Science University and the Knight Cancer Institute, discusses whether adding pembrolizumab can overcome resistance to enzalutamide, and whether treatment with the immune checkpoint inhibitor should be continuous.